About BioSenic SA

Company Description

BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair.

Our expertise is focused on bone cell therapy and the therapeutic use of arsenic trioxide (As2O3). BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for bone and autoimmune and inflammatory diseases.

BioSenic has a broad and diverse portfolio of solutions in clinical development in a variety of therapeutic areas targeting markets characterized by significant unmet medical needs and limited innovation.

Year founded

2006

Served area

Worldwide

Shareholder information

Shares outstanding

31,229,152

IPO

Feb. 6, 2015

Stock exchange(s)

Euronext Brussels

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.